Previous Close | 6.58 |
Open | 6.29 |
Bid | 0.00 x 2200 |
Ask | 0.00 x 900 |
Day's Range | 6.12 - 8.18 |
52 Week Range | 2.87 - 17.85 |
Volume | |
Avg. Volume | 8,623,811 |
Market Cap | 522.886M |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -10.43 |
Earnings Date | Nov 03, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for BLUE
The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.
Somerville gene therapy firm bluebird bio Inc. has scored its first approval from the U.S. Food and Drug Administration following its business split late last year.
SOMERVILLE, Mass., August 17, 2022--Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO, including an innovative, outcomes-based contract offering and a comprehensive patient support program.